Capstone Therapeutics (NASDAQ:CAPS) Posts Earnings Results, Misses Expectations By $41.39 EPS

Capstone Therapeutics (NASDAQ:CAPS) posted its quarterly earnings results on Thursday. The company reported ($38.40) EPS for the quarter, missing analysts’ consensus estimates of $2.99 by ($41.39), FiscalAI reports. The company had revenue of $19.96 million during the quarter, compared to the consensus estimate of $22.50 million. Capstone Therapeutics had a negative return on equity of 144.43% and a negative net margin of 36.51%.

Capstone Therapeutics Stock Down 11.4%

Shares of CAPS stock traded down $0.23 during mid-day trading on Thursday, hitting $1.79. The stock had a trading volume of 92,630 shares, compared to its average volume of 89,724. Capstone Therapeutics has a 12-month low of $1.78 and a 12-month high of $34.80. The firm has a market capitalization of $1.65 million, a P/E ratio of -0.02 and a beta of -1.35. The firm’s 50-day moving average is $3.88 and its two-hundred day moving average is $10.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Capstone Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.